Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328910 | 0.92 | HSD11B1 (0.86) | HSD11B1HSD11B2CYP2D6DPP4DPP8 | |
| SCHEMBL328817 | 0.91 | HSD11B1 (0.83) | HSD11B1HSD11B2CYP2D6DPP4DPP8 | |
| SCHEMBL19256171 | 0.82 | HSD11B1 (1.00) | HSD11B1HSD11B2CYP2D6 | |
| SCHEMBL4791837 | 0.82 | HSD11B1 (1.00) | HSD11B1HSD11B2CYP2D6 | |
| SCHEMBL328819 | 0.82 | HSD11B1 (1.00) | HSD11B1HSD11B2CYP2D6 | |
| SCHEMBL4791839 | 0.82 | HSD11B1 (1.00) | HSD11B1HSD11B2CYP2D6 | |
| SCHEMBL328942 | 0.80 | HSD11B1 (0.86) | HSD11B1HSD11B2CYP2D6 | |
| SCHEMBL328846 | 0.79 | HSD11B1 (0.85) | HSD11B1HSD11B2CYP2D6DPP4DPP8 | |
| SCHEMBL328769 | 0.79 | HSD11B1 (1.00) | HSD11B1HSD11B2CYP2D6DPP4DPP8 | |
| SCHEMBL328784 | 0.78 | HSD11B1 (0.83) | HSD11B1HSD11B2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2015-04-09 | — | — | US | claimed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | claimed |
| EP-2007719-B1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-05-02 | — | — | EP | claimed |
| EP-2407452-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2012-01-18 | — | — | EP | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| WO-2010123838-A2 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | claimed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | claimed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | claimed |
| US-7737137-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | claimed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| EP-2007719-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2008-12-31 | — | — | EP | claimed |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | claimed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | claimed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | claimed |
| WO-2007118185-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | claimed |
| US-9464072-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885CYP2D6 182/4885 |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885CYP2D6 447/4885 |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | HSD11B1 2/4885HSD11B2 1/4885CYP2D6 1094/4885 |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885CYP2D6 714/4885 |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885CYP2D6 447/4885 |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885CYP2D6 447/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885CYP2D6 244/4885 |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.